Financial News · Live Terminal

Page 223 of 372

Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable June 10 to Shareholders of Record as of May 15

STAG Industrial Faces Heavy Lease Roll and Falling Occupancy Rates, RBC Says

STAG Industrial (STAG) reported solid Q1 leasing activity but it is still navigating a heavy lease roll and portfolio-wide occupancy is expected to decline, RBC Capital Markets said in a note emailed Monday.The brokerage expects funds from operations of $2.64 per share in 2026, slightly lowered its 2027 estimate to $2.81 per share, and introduced a 2028 estimate at $2.91 per share.The 2026 FFO estimate reflects the high end of management's guidance range, implying healthy same store net operating income growth and incremental investment activity, the firm said. The 2028 estimate assumes slightly better organic growth and similar external growth, but the anticipated debt refinancing could potentially reduce the overall growth by 100 basis points, according to the note.The company recently purchased a Dallas land site that will support a $38 million development project spanning 340,000 square feet, which is expected to deliver a 7.4% yield, the brokerage added.RBC maintained a sector perform rating on STAG Industrial with a price target of $42.Price: $37.96, Change: $-0.62, Percent Change: -1.61%

$STAG

Wire58d ago

BofA Securities Lifts Microchip Technology Price Target to $112 From $95, Maintains Buy Rating

Microchip Technology (MCHP) has an average rating of overweight and mean price target of $91.09, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $94.72, Change: $+0.77, Percent Change: +0.82%

$MCHP

Wire58d ago

IonQ Likely to Benefit From Quantum Sector Tailwinds, Wedbush Says

IonQ (IONQ) is expected to benefit from sector tailwinds following Nvidia's (NVDA) launch of its Ising open AI models to accelerate the path to useful quantum computers, Wedbush Securities said in a Monday note.IonQ was cited directly by Nvidia as one of the early adopters of Ising Calibration, the report said."This signals that IonQ's trapped-ion architecture is being recognized by the industry's most influential infrastructure player as production-ready and technically credible," the note said.The report said it also deepens the commercial relationship between IonQ and Nvidia and embeds IonQ within the hybrid stack NVDA is building around CUDA-Q and NVQLink.The report also said IonQ has "consistently" beaten its own guidance and raised forward estimates, and it could continue this trend with its Q1 results, due for release on May 6. IonQ forecast Q1 revenue of about $50 million.Wedbush reiterated its outperform rating and $60 price target.Price: $47.45, Change: $+1.25, Percent Change: +2.71%

$IONQ

Wire58d ago

Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC Says

Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital said in a Friday note.According to the note, Moderna's Q1 results were driven by a stronger-than-expected COVID franchise, largely supported by international revenue recognition, while management reaffirmed its full-year outlook across revenue, R&D, SG&A, and capital expenditures.RBC highlighted ongoing momentum in Moderna's infectious disease pipeline, including upcoming flu vaccine regulatory milestones, progress on a flu-COVID combination shot, and advancement of its norovirus program, with data expected later this year depending on case accruals.On oncology, RBC noted upcoming catalysts for Moderna, including potential Phase III adjuvant melanoma data, updated Phase II results at ASCO, and a new pivotal early-stage non-small cell lung cancer study using its cancer vaccine platform.RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35.Shares of Moderna were up over 4% in Monday trading.Price: $47.57, Change: $+2.20, Percent Change: +4.85%

$MRNA

Wire58d ago

Reynolds Consumer Products Faces Aluminum Cost Pressures, RBC Says

Reynolds Consumer Products (REYN) remains on the sidelines as rising aluminum prices and broader commodity cost pressures weigh on its outlook, RBC Capital Markets said in a Monday note.Consumer headwinds have affected demand across the company's categories and could worsen if the Middle East conflict drives higher inflation, analysts wrote, while noting some improvement in consumption trends.The company is likely to post in-line Q1 results, supported by encouraging recent performance. However, inflation in key production inputs, primarily aluminum, could pressure margins.Reynolds Consumer is scheduled to report its Q1 results Wednesday.Channel checks indicated that the company is gaining volume share in the waste bags segment following increased promotional and pricing activity, according to the brokerage. The investment firm said that the foil pricing has so far shown limited demand elasticity.Reynolds Consumer has exposure to industrial and energy commodities, principally aluminum, and also depends on third-party rail and truck networks, making it vulnerable to volatility in freight and logistics labor costs, RBC stated.The brokerage has a sector perform rating on the stock, with a price target of $24 per share.Price: $20.82, Change: $+0.05, Percent Change: +0.22%

$REYN

Wire58d ago

Intel Sees Broad-Based Demand in CPUs Continuing, RBC Says

Intel (INTC) is looking positive in its near-term prospects, with the company expecting broad-based demand in central processing units to persist through the year and product sales mix to drive average selling prices, RBC Capital Markets said in a Monday note.Overall CPU demand continues to exceed production capacity, with cloud companies showing the strongest growth and enterprise customers also faring well, RBC analysts said. The product mix has moved more to CPUs with larger dies, which has boosted average selling prices, and the company has raised prices to reflect cost inflation and the strong demand environment, the analysts said.Intel is seeing CPU density increase, with agentic AI boosting higher CPU-to-GPU ratios compared to traditional AI training workloads, according to the note. Physical AI and edge computing is also driving up demand for CPUs, on which it relies on for real-time inferencing, the note said.Intel seems to be confident in its H2 outlook, the analysts noted.RBC maintained the company's stock rating at sector-perform and price target at $80.Price: $98.23, Change: $-1.39, Percent Change: -1.39%

$INTC

Wire58d ago

Edgewell Personal Care Moving in the 'Right' Direction, RBC Says

Edgewell Personal Care (EPC) is moving in the "right" direction after a period of "persistent underperformance," RBC Capital Markets analysts said in a Monday note.The company is scheduled to report its fiscal Q2 financial results on Wednesday.Analysts said they do not expect any additional surprises in Edgewell's fiscal Q2 financial report, and instead look for indications that its initiatives remain on track to drive improvement.RBC said there are some "positive" consumption data points for the quarter, but it remains wary of "fragile" demand conditions.Analysts said the conflict in the Middle East has the potential to pressure demand and costs.RBC has an outperform rating on the stock and a $26 price target.Price: $22.22, Change: $-0.34, Percent Change: -1.51%

$EPC

Wire58d ago

Colgate-Palmolive Set for Organic Sales Growth Rebound, Morgan Stanley Says

Colgate-Palmolive (CL) is poised to return to 3% to 4% organic sales growth after a rebound to about 3.5% in Q1, with momentum expected to build in H2, Morgan Stanley said Sunday in a report.Colgate-Palmolive's difficult 2025 is "in the rear-view mirror," with organic sales growth rebounding to 3% in Q4 from 1.2% in Q3 and improving into early 2026, supported by "solid pricing power," 45% exposure to faster-growing emerging markets and a likely bottom in North America, the report said.Further improvement in organic sales growth is expected in the near term as the drag from private-label discontinuations fades and North America stabilizes, the report said.Colgate-Palmolive on Friday reported Q1 adjusted EPS of $0.97, beating estimates, with stronger-than-expected 2.9% organic sales growth, while maintaining its 2026 outlook, despite $300 million in cost pressures expected to be partly offset by savings, the report said.Morgan Stanley raised its price target on Colgate-Palmolive stock to $100 from $95 and kept its overweight rating, naming the company as a top pick in the household and personal care sector.Price: $85.73, Change: $-1.53, Percent Change: -1.75%

$CL

Wire58d ago

Prudential Financial Recovery Uncertain Amid Japan Sales Suspension, Morgan Stanley Says

Prudential Financial (PRU) faces continued pressure from its voluntary suspension of new policy sales in Japan, with uncertainty around recovery in sales, revenue, and reputation, Morgan Stanley said in a note Monday.The company updated its earnings outlook after its Prudential Life Insurance unit in Japan decided to extend a voluntary sales suspension by another 180 days through November. Media reports also indicate that Japan's Financial Services Agency is conducting on-site inspections, and there are suggestions the company may have been aware of some of the problems, according to the note.Based on past cases of misconduct in Japan's life insurance sector, Morgan Stanley said the situation may not be resolved soon. While Prudential's case is different, "we believe it is more likely to experience longer term structural pressure on sales and annualized net premiums, given the breadth of the misconduct and the associated sales suspension," the firm said.Based on an estimated pretax operating earnings impact of $525 million to 575 million in 2026 and $400 million to $450 million in 2027, the firm said it is reducing its earnings per share estimates to $13.43 for 2026 and $14.73 for 2027.Morgan Stanley downgraded Prudential Financial from equal-weight to underweight, and cut its price target to $92 from $106.Price: $98.40, Change: $-0.22, Percent Change: -0.22%

$PRU

Wire58d ago

Bob's Discount Furniture Faces Softer Category Demand, Rising Costs Ahead of Q1 Results, RBC Says

Bob's Discount Furniture is expected to report in-line Q1 results, but channel checks point to softer category demand and rising costs, which could pressure the stock in the near-term, especially with two quarters of tough comparisons ahead, RBC Capital Markets said in a note emailed Monday.For Q1, the firm models comparable sales growth of 1.3%, implying decent market share gains versus the category, which declined by low-single-digits during the quarter, according to the note.Transaction data supports management's view that relative Q1 weakness was isolated to January and February due to winter storms and improved later. RBC said its channel work suggests that the overall category slowed in April.The brokerage thinks Bob's might benefit from higher tax refunds year-over-year and notes that management attributes comp outperformance in the past year partially to improved conversion thanks to a new retail operating system launched in 2024's Q4.The company will report Q1 results before the market opens on Thursday.RBC maintained an outperform rating on Bob's Discount Furniture and lowered the price target to $18 from $25.Price: $10.41, Change: $-0.66, Percent Change: -5.96%

$BOBS

Wire58d ago

Citigroup Lifts Price Target on EQT to $70 From $66, Maintains Buy Rating

EQT (EQT) has an average rating of overweight and mean price target of $71.02, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $59.45, Change: $+0.79, Percent Change: +1.35%

$EQT

Wire58d ago

Update: Morgan Stanley Raises Price Target on Estee Lauder to $90 From $85, Keeps Equalweight Rating

(Updates with the analyst's commentary.)Morgan Stanley raised its price target on Estee Lauder (EL) to $90 from $85 while maintaining its equalweight rating.The brokerage said in a Monday note it is "encouraged" by Organic Sales Growth and with "a faster margin recovery" but held back by OSG concentration and "skepticism around a potential Puig deal."Morgan Stanley said OSG results are "China driven" and while emerging markets and online continue to outperform, growth is "limited" outside these areas, with The Americas experiencing a flat OSG.The brokerage said it questions whether acquiring beauty firm Puig is "worth the opportunity cost," given the company's complexity and "the cultural risk of merging two family-run companies" while Estee Lauder is itself "undergoing a complex initial restructuring."Estee Lauder has an average rating of overweight and mean price target of $96.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $80.95, Change: $+1.65, Percent Change: +2.08%

$EL

Wire58d ago

Barclays Adjusts Price Target on Crown Castle to $92 From $91, Maintains Equalweight Rating

Crown Castle (CCI) has an average rating of overweight and mean price target of $97.62, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $90.16, Change: $+0.90, Percent Change: +1.01%

$CCI

Wire58d ago

Barclays Adjusts Price Target on CBRE Group to $178 From $175, Maintains Overweight Rating

CBRE Group (CBRE) has an average rating of buy and mean price target of $181.73, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $141.99, Change: $+0.18, Percent Change: +0.13%

$CBRE

Wire58d ago

Jefferies Adjusts Price Target on Quanta Services to $857 From $654, Maintains Buy Rating

Quanta Services (PWR) has an average rating of overweight and mean price target of $778.23, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $747.48, Change: $+5.27, Percent Change: +0.71%

$PWR

Wire58d ago

GlobalFoundries Likely to Post a Slight Q1 Beat, Wedbush Says

GlobalFoundries (GFS) likely to post a slight Q1 beat as concerns around handset and impact from memory shortage do not appear to have negatively affected foundry dynamics, Wedbush said in a Monday research report.Heightened requirements on the specialty application front should benefit the company likely through the long-term, analysts wrote. The company is due to report Q1 results on May 5.The company could prioritize expanded opportunities in the Gallium-Nitride segment as the demand for the semiconductor material is set to grow from the rising usage in data center and satellite applications, according to the note.The company will likely continue to moderate capacity additions and optimize production for higher margin specialty opportunities, the brokerage stated.The brokerage reiterated its neutral rating on the stock and price target of $50.Price: $67.54, Change: $+2.63, Percent Change: +4.05%

$GFS

Wire58d ago

Estee Lauder's Turnaround Progressing, Puig Deal Complicates Narrative, Morgan Stanley Says

Estee Lauder's (EL) turnaround of its base business is progressing well and the company is seeing sufficient improvement in its organic sales growth to confirm the high end of its previous full-year sales range, Morgan Stanley said in a note emailed Monday with a review of the company's fiscal Q3 results.Also, the company's Q3 earnings per share upside backed an increase in its 2026 guidance, as well as a strong early 2027 outlook, even amid the pressure caused by the conflict in Iran, the note said.Morgan Stanley said, however, Estee Lauder's assumption that the prestige beauty business will accelerate in 2027 may be optimistic, adding the company was "incentivized to put its best foot forward ahead of potential equity in a Puig deal."There are some questions on "whether the execution/cultural risk of a large acquisition is worth the opportunity cost [versus Estee Lauder's] base business turnaround despite sizeable potential EPS accretion," the note said.The investment firm noted Puig is a complex target due to its big size, fragmented brand/geographic exposure, and the cultural risk of combining family-run companies."We remain on the sidelines here, waiting to see how strategic discussions play out, and looking for more confidence in sustained" Estee Lauder organic sales growth, the note said.Morgan Stanley kept its equal-weight rating on Estee Lauder and increased the company's price target to $90 from $85.Price: $82.07, Change: $+2.77, Percent Change: +3.49%

$EL

Wire58d ago

Ashland's Fiscal Q2 a 'Mixed Bag' With Downward EBITDA Revisions, Morgan Stanley Says

Ashland's (ASH) fiscal Q2 results were a "mixed bag" relative to expectations as a clear end to downward revisions to earnings before interest, taxes, depreciation and amortization has not yet materialized, Morgan Stanley said in a Monday note.Fiscal Q2 volumes surpassed Morgan Stanley's expectations, which supports the case for Ashland's base business resilience and the achievability of its growth initiatives, according to the note. The company's commentary on price cost was also in line with the analysts' framework of "modest favorability" in fiscal H2, the note said.However, the company has to contend with new operational issues, such as those in its manufacturing plants in Calvert City and Hopewell, which have impacted profit by about $30 million in combined costs, the analysts said. They noted that investors will study if these headwinds are recurring or not.Ashland's guidance is weighted towards fiscal Q4 and is dependent on sustained volume momentum or price outperformance, according to the note.Morgan Stanley maintained the company's stock rating at equal-weight and lowered the price target to $58 from $63.Price: $53.17, Change: $+1.35, Percent Change: +2.61%

$ASH

Showing 4441-4460 of 7433

Wire58d ago

Financial News · Live Terminal

Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable June 10 to Shareholders of Record as of May 15

STAG Industrial Faces Heavy Lease Roll and Falling Occupancy Rates, RBC Says

BofA Securities Lifts Microchip Technology Price Target to $112 From $95, Maintains Buy Rating

IonQ Likely to Benefit From Quantum Sector Tailwinds, Wedbush Says

Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC Says

Top Midday Stories: GameStop Submits $55.5 Billion Bid to Acquire eBay; Amazon Launches Supply Chain Services

Reynolds Consumer Products Faces Aluminum Cost Pressures, RBC Says

Intel Sees Broad-Based Demand in CPUs Continuing, RBC Says

Edgewell Personal Care Moving in the 'Right' Direction, RBC Says

Colgate-Palmolive Set for Organic Sales Growth Rebound, Morgan Stanley Says

Prudential Financial Recovery Uncertain Amid Japan Sales Suspension, Morgan Stanley Says

Bob's Discount Furniture Faces Softer Category Demand, Rising Costs Ahead of Q1 Results, RBC Says

Citigroup Lifts Price Target on EQT to $70 From $66, Maintains Buy Rating

Update: Morgan Stanley Raises Price Target on Estee Lauder to $90 From $85, Keeps Equalweight Rating

Barclays Adjusts Price Target on Crown Castle to $92 From $91, Maintains Equalweight Rating

Barclays Adjusts Price Target on CBRE Group to $178 From $175, Maintains Overweight Rating

Jefferies Adjusts Price Target on Quanta Services to $857 From $654, Maintains Buy Rating

GlobalFoundries Likely to Post a Slight Q1 Beat, Wedbush Says

Estee Lauder's Turnaround Progressing, Puig Deal Complicates Narrative, Morgan Stanley Says

Ashland's Fiscal Q2 a 'Mixed Bag' With Downward EBITDA Revisions, Morgan Stanley Says

Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable June 10 to Shareholders of Record as of May 15

STAG Industrial Faces Heavy Lease Roll and Falling Occupancy Rates, RBC Says

BofA Securities Lifts Microchip Technology Price Target to $112 From $95, Maintains Buy Rating

IonQ Likely to Benefit From Quantum Sector Tailwinds, Wedbush Says

Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC Says

Top Midday Stories: GameStop Submits $55.5 Billion Bid to Acquire eBay; Amazon Launches Supply Chain Services

Reynolds Consumer Products Faces Aluminum Cost Pressures, RBC Says

Intel Sees Broad-Based Demand in CPUs Continuing, RBC Says

Edgewell Personal Care Moving in the 'Right' Direction, RBC Says

Colgate-Palmolive Set for Organic Sales Growth Rebound, Morgan Stanley Says

Prudential Financial Recovery Uncertain Amid Japan Sales Suspension, Morgan Stanley Says

Bob's Discount Furniture Faces Softer Category Demand, Rising Costs Ahead of Q1 Results, RBC Says

Citigroup Lifts Price Target on EQT to $70 From $66, Maintains Buy Rating

Update: Morgan Stanley Raises Price Target on Estee Lauder to $90 From $85, Keeps Equalweight Rating

Barclays Adjusts Price Target on Crown Castle to $92 From $91, Maintains Equalweight Rating

Barclays Adjusts Price Target on CBRE Group to $178 From $175, Maintains Overweight Rating

Jefferies Adjusts Price Target on Quanta Services to $857 From $654, Maintains Buy Rating

GlobalFoundries Likely to Post a Slight Q1 Beat, Wedbush Says

Estee Lauder's Turnaround Progressing, Puig Deal Complicates Narrative, Morgan Stanley Says

Ashland's Fiscal Q2 a 'Mixed Bag' With Downward EBITDA Revisions, Morgan Stanley Says